Patents Examined by Christine M. Nucker
  • Method for detecting antibody against Staphylococcus aureus for replication protein B sequence 275-290 and Arg-Lys-Leu in human body fluids
    Patent number: 5593849
    Abstract: This is an immunochemical assay that uses enzyme-linked immunosorbence to detect the presence of antibodies against environmental protein sequences that mimic the human opioid peptide dynorphin in samples of human body fluid. The assay makes it possible to correlate and diagnose psychobiological or medical disorders related to alterations in the normal levels of dynorphin peptides or their receptors.
    Type: Grant
    Filed: February 24, 1994
    Date of Patent: January 14, 1997
    Inventor: Benjamin F. Roy
  • Polypeptide-induced monoclonal receptors to protein ligands
    Patent number: 5591587
    Abstract: Monoclonal receptors raised to immunogenic polyeptides whose amino acid residue sequences correspond to sequences of oncoprotein ligands are disclosed, as are method for the production of those receptors and products and methods that utilize them. The monoclonal receptors bind both to the oncoprotein ligand to a portion of which the polypeptide corresponds in sequence, and to the immunogenic polypeptide to which the receptors were raised.
    Type: Grant
    Filed: August 23, 1994
    Date of Patent: January 7, 1997
    Assignee: The Scripps Research Institute
    Inventor: Henry L. Niman
  • Recombinant cytomegalovirus vaccine
    Patent number: 5591439
    Abstract: The present invention provides a non-defective adenovirus recombinant expression system for the expression of the HCMV gB subunit and for the expression of non-structural immediate-early exon 4 proteins, said recombinant HCMV-expressing adenovirus being useful as a vaccine.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: January 7, 1997
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Stanley A. Plotkin, Robert P. Ricciardi, Ewa Gonczol
  • Method of determining the presence of endotoxin in a sample
    Patent number: 5591628
    Abstract: There is disclosed a method for determining the presence of endotoxin or an endotoxin like substance in a sample, as well as a monoclonal antibody and test kit useful in the method.
    Type: Grant
    Filed: May 28, 1990
    Date of Patent: January 7, 1997
    Inventors: Leif B.ae butted.k, Claus Koch
  • Probes, diagnostic method and immunization method based on papillomavirus types HPV 49 and HPV 50
    Patent number: 5591574
    Abstract: The invention relates to papillomavirus probes derived from new DNA-HPVs deposited with the C.N.C.M. on May 6, 1988, under the following filing numbers:______________________________________ PGEM 4 HPV49: I-754 PSP 65 HPV50: I-755 PSP 64 HPV54: I-756 PGEM 4 HPV55A: I-757 PGEM 4 HPV55B: I-758 ______________________________________These probes can be used for in vitro detection of:in the case of HPV49: warts of the skin (in particular, common and plantar warts) and the differential diagnosis of epidermodysplasia verruciformis,in the case of HPV50: epidermodysplasia verruciformis, intraepithelial neoplasias and cutaneous cancer,in the case of HPV55: genital neoplasias and cancers of the uterine cervix,in the case of HPV55: genital nepolasias and cancers of the uterine cervix, condylomas and papillomas.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 7, 1997
    Assignee: Institut Pasteur
    Inventors: Gerard Orth, Michel Favre, Dina Kremsdorf, G erard Pehau-Arnaudet
  • Electrochemiluminescent rhenium moieties and methods for their use
    Patent number: 5591581
    Abstract: Electrochemiluminescent moieties having the formula(Re(P).sub.m (L.sup.1).sub.n (L.sup.2).sub.o (L.sup.3).sub.p (L.sup.4).sub.t (B).sub.uwhereinP is a polydentate ligand of Re;L.sup.1, L.sup.2, L.sup.3 and L.sup.4 are ligands of Re, each of which may be the same as or not the same as each other ligand;B is a substance which is a ligand of Re or is conjugated to one or more of P, L.sup.1, L.sup.2, L.sup.3 and L.sup.4 ;m is an integer equal to or greater than 1;each of n, o, p, q, r and s is zero or an integer;t is an integer equal to or greater than 1; andu is an integer equal to or greater than 1;P, L.sup.1, L.sup.2, L.sup.3, L.sup.4 and B being of such composition and number that the chemical moiety can be induced to electrochemiluminesce and the total number of bonds to Re provided by the ligands of Re being equal to the coordination number of Re are disclosed.
    Type: Grant
    Filed: April 15, 1994
    Date of Patent: January 7, 1997
    Assignee: IGEN, Inc.
    Inventors: Richard J. Massey, Michael J. Powell, Walter J. Dressick, Jonathan K. Leland, Janel K. Hino, Mohindar S. Poonian, Leopoldo D. Ciana
  • Vaccine against Pasteurella
    Patent number: 5587166
    Abstract: A vaccine against Pasteurella comprising a proteinaceous material isolated from Pasteurella grown under iron-restricted conditions, but not from Pasteurella grown under normal conditions in vitro, which reacts in an immunoblotting test against the serum of a convalescent sheep or cow which has recovered from an infection by Pasteurella of the same serotype, together with an adjuvant.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: December 24, 1996
    Assignee: British Technology Group Limited
    Inventor: William Donachie
  • Method for detection or quantitation of an analyte using an analyte dependent enzyme activation system
    Patent number: 5583001
    Abstract: The present invention concerns a method to catalyze reporter deposition to improve detection or quantitation of an analyte in a sample by amplifying the detector signal which comprises reacting an analyte dependent enzyme activation system with a conjugate consisting of a detectably labeled substrate specific for the enzyme system, said conjugate reacts with the analyte dependent enzyme activation system to form an activated conjugate which deposits substantially wherever receptor for the activated conjugate is immobilized, said receptor not being reactive with the analyte dependent enzyme activation system.In another embodiment the invention concerns an assay for detecting or quantitating the presence or absence of an analyte in a sample using catalyzed reporter deposition to amplify the reporter signal.
    Type: Grant
    Filed: May 4, 1994
    Date of Patent: December 10, 1996
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Mark N. Bobrow, Gerald J. Litt
  • Process of screening plasma samples for effective antibody titers against respiratory viruses
    Patent number: 5582827
    Abstract: A process for identifying plasma samples containing effective antibody titers for the treatment and/or prophylaxis of infections caused by a respiratory virus. The process comprises contacting a plasma sample containing antibodies against a respiratory virus with the respiratory virus. The mixture of plasma sample and virus is then contacted with a plurality of cells. The remaining non-neutralized virus in the sample is then determined through an immunoassay following replication of the virus in the cells. Plasma samples which, at a preselected minimum antibody titer value, prevent viral replication in the cells, are then selected. Plasma from which the selected samples were derived are then pooled to provide an immunoglobulin preparation having increased effectiveness in the prophylaxis and/or treatment of infections caused by the respiratory virus.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: December 10, 1996
    Assignee: Massachusetts Health Research Institute, Inc.
    Inventors: George R. Siber, Jeanne Leszczynski
  • Human lymphoid cells expressing human immunodeficiency virus envelope protein gp160
    Patent number: 5580720
    Abstract: The present invention provides mammalian cells modified to stably express at least the entire human immunodeficiency virus-1 envelope protein gp160. The invention provides a vaccine comprising the cells of the invention. The invention also provides methods for screening compounds for their ability to inhibit formation of syncytia between cells that express HIV-1 gp160 and cells that express CD4 comprising mixing cells of invention, cells that express CD4 on their surfaces, and a test compound for a length of time sufficient for syncytia to form; and then determining the amount of syncytia formation.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 3, 1996
    Assignee: SmithKline Beecham Corporation
    Inventors: Zdenka L. Jonak, Christine Debouck, Robert Clark, Stephen Trulli
  • Antihuman pulmonary adenocarcinoma monoclonal antibody
    Patent number: 5580740
    Abstract: An antihuman pulmonary adenocarcinoma monoclonal antibody ALC-390 and a process for producing thereof are disclosed. This monoclonal antibody, which belongs to IgG class and is reactive with human pulmonary adenocarcinoma cell membranes and recognizes protein as the antigen, is highly useful in the pathological diagnosis of pulmonary adenocarcinoma and in the treatment of the same.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: December 3, 1996
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Hajime Yoshida, Kenya Shitara
  • Peptides of human immunodeficiency virus type 2 (HIV-2) and in vitro diagnostic methods and kits employing the peptides for the detection of HIV-2
    Patent number: 5580739
    Abstract: A novel lentivirus, designated the human immunodeficiency virus type 2 (HIV-2.sub.ROD), was isolated from West African patients with acquired immune deficiency syndrome (AIDS). A recombinant lambda phage library was constructed from HIV-2.sub.ROD -infected CEM genomic DNA. Overlapping molecular clones were obtained and the nucleotide sequence of the complete 9.5-kilobase (kb) HIV-2.sub.ROD genome ascertained. The genetic organization of HIV-2 is analogous to that of other retroviruses and consists of the 5'LTR-gag-pol-central region-env-nef-3'LTR. The central region also encodes for the regulatory proteins Tat and Rev, as well as the ancillary proteins Vif, Vpr, and Vpx. The proteins encoded by this proviral clone will provide novel immunologic, biochemic, and diagnostic reagents useful for the detection of HIV-2.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: December 3, 1996
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Antibodies to the slam protein expressed on activated T cells
    Patent number: 5576423
    Abstract: Purified genes which encode a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: November 19, 1996
    Assignee: Schering Corporation
    Inventors: Gregorio Aversa, Chia-Chun J. Chang, Benjamin G. Cocks, Jan E. de Vries
  • Molecular clones of HIV-1 viral strains MH-ST1 and BA-L, and uses thereof
    Patent number: 5576000
    Abstract: The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST 1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: November 19, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Marvin S. Reitz, Jr., Genoveffa Franchini, Phillip D. Markham, Robert C. Gallo, Franco C. Lori, Mikulas Popovic, Suzanne Gartner
  • Process and reagent for specific determination of pancreatic alpha amylase
    Patent number: 5573918
    Abstract: The present invention provides a process for the specific determination of pancreatic alpha-amylase in the presence of salivary alpha-amylase in body fluids, especially in serum, plasma, duodenal juice or urine, by reaction with a system for the detection of alpha-amylase in the presence of a monoclonal antibody which inhibits salivary alpha-amylase wherein, as inhibitor, there is used a first monoclonal antibody which specifically inhibits the salivary enzyme by less than 97%, in combination with a second monoclonal anti-saliva alpha-amylase antibody which inhibits this enzyme by less than 10%.
    Type: Grant
    Filed: September 19, 1991
    Date of Patent: November 12, 1996
    Assignee: Boehringer Mannheim GmbH
    Inventors: Helmut Lenz, Martin Gerber, Winfried Albert
  • N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp derivatives
    Patent number: 5574013
    Abstract: Novel peptoids of .alpha.-substituted Trp derivatives useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to withdrawal from chronic treatment or use of nicotine, diazepam, alcohol, cocaine, caffeine, or opioids. The compounds are also useful in the treatment and/or prevention of panic attacks. Also disclosed are pharmaceutical compositions and methods of treatment using the peptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare diagnostic compositions.
    Type: Grant
    Filed: May 27, 1993
    Date of Patent: November 12, 1996
    Assignee: Warner-Lambert Company
    Inventors: David C. Horwell, Maryin C. Pritchard, Edward Roberts
  • Placental isoferritins for the prognosis and diagnosis of immunosuppression
    Patent number: 5571678
    Abstract: Methods for the diagnosis and prognosis of immunosuppressive conditions are disclosed, involving the detection of a particular isoform of ferritin, placental ferritin (PLF), in patient samples such as sera or on peripheral blood lymphocytes. PLF is elevated in immunosuppressed patients at early stages of disease; by contrast, adult insoferritins are elevated at late stages of immunodeficiency. Depending upon the nature of the disease associated with the immunodeficiency, the elevated levels of PLF detected at early stages may remain elevated or diminish as disease progresses. Examples are described in which elevated levels of PLF were detected at very early stages of of HIV-infection. The elevated levels diminished as disease progressed from ARC to AIDS. By contrast, adult isoforms of ferritin became elevated at late stages of disease.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: November 5, 1996
    Inventors: Chaya Moroz, S. Leslie Misrock
  • The cellular receptor for the CS3 peptide of human immunodeficiency virus
    Patent number: 5567805
    Abstract: The present invention relates to methods of inhibiting HIV-mediated cell killing which comprises inhibiting the interaction between the CS3 region and viral gp41 and its receptor on the surface of lymphocytes. The invention provides for methods which employ peptides, peptide derivatives, or antibodies to inhibit the CS3/CS3 receptor interaction. In addition, the invention also relates to the CS3 receptor.The present invention is based in part on the discovery that a CS3 specific cellular receptor is widely distributed on human lymphocytes and forms a 108 kd complex with CS3-HSA peptide conjugate. It was further discovered that CS3 peptide effectively blocks HIV mediated cell infection and killing. Therefore, the present invention provides for methods of treatment and prophylaxis of HIV infection as well as a means for better understanding the physiology of acquired immunodeficiency syndrome (AIDS).
    Type: Grant
    Filed: September 7, 1994
    Date of Patent: October 22, 1996
    Assignee: Administrators of the Tulane Educational Fund
    Inventors: Lee A. Henderson, David H. Coy, Robert F. Garry, Jr.
  • Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
    Patent number: 5567592
    Abstract: A screening method for the identification of bioenhancers that increase the bioavailability of an orally administered pharmaceutical compound through the inhibition of P-glycoprotein transport activity in the gut of a mammal is disclosed. These compounds increase the systemic availability of a pharmaceutical compound when administered prior to, or concurrently with, that compound.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: October 22, 1996
    Assignee: Regents of the University of California
    Inventors: Leslie Benet, Chi Y. Wu
  • Oligosaccharide sequencing
    Patent number: RE35417
    Abstract: A method of oligosaccharide sequencing in which the components are determined essentially simultaneously is disclosed which comprises a series of steps as follows:A. Placing an identifying label on the reducing terminal residue of the oligosaccharide to be sequenced,B. Dividing said oligosaccharide into a plurality of separate portions of known integer amounts,C. Treating each said portion with a different reagent mix to thereby provide a series of reaction mixtures,D. Pooling known integer amounts of the products from each separate reaction mixture to give a product pool,E. Performing an analysis on said product pool which measures the molar proportions of the reaction products, andF. Reconstructing or identifying the starting oligosaccharide from the molar prevalence of said reaction products.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: December 31, 1996
    Assignee: Oxford GlycoSystems Ltd.
    Inventors: Thomas W. Rademacher, Mark R. Wormald, Raj. B. Parekh, Christopher J. Edge, Raymond A. Dwek